Medios AG (ILM1.DE) Stock Analysis & Winston Score
Medios AG is a German healthcare company that makes and distributes specialty medicines. It focuses on personalized therapies — drugs that are custom-made for individual patients — and supplies these to pharmacies and hospitals across Germany. The company is one of the larger players in Germany's growing market for specialty pharmaceuticals, including treatments for cancer, HIV, and rare diseases. Medios earns money by manufacturing compounded drugs in its own facilities and by distributing specialty medicines to partner pharmacies. It operates almost entirely within Germany, with annual revenues in the hundreds of millions of euros. Its main competitive advantage is its integrated model — combining manufacturing and distribution under one roof — which gives it some pricing power with pharmacy partners. However, the company's thin margins leave little room for error, and its growth depends heavily on expanding its network of partner pharmacies and increasing the volume of high-value compounded prescriptions it fills.
Winston Score: 42/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Weak (5/30)
- Growth: Mixed (5/20)
- Cash Flow: Strong (7/10)
- Stability: Good (6/10)
- Valuation: Strong (7/10)
- Ownership: Good (10/15)
Key Facts
Price: €10.82
Market Cap: €276M
Sector: Healthcare
Industry: Medical - Distribution
Exchange: Frankfurt Stock Exchange


